Navigation Links
Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
Date:1/17/2012

WAYNE, N.J., Jan. 17, 2012 /PRNewswire/ -- Bayer HealthCare today announced latest data on its investigational compound regorafenib (BAY 73-4506) from the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial. The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median OS: 6.4 months vs. 5.0 months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.(1) This late-breaking abstract, with these updated data, will be presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic and co-principal investigator of the CORRECT study, in an oral abstract session (LBA No. 385, January 21, 2012 from 2:30 p.m. - 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.

Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HR=0.49, p<0.000001, median PFS: 1.9 months vs. 1.7 months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo. The difference in objective response rate between the two arms (1.0% vs. 0.4%) did not reach statistical significance.(1)

The most common drug-related, treatment-emergent adverse events included fatigue (47.4% vs. 28.1%), hand-foot skin reaction (46.6% vs. 7.5%), diarrhea (33.8% vs. 8.3%), anorexia (30.4% vs. 15.4%), hypertension (27.8% vs. 5.9%), oral mucositis (27.2% vs. 3.6%) and rash/desquamation (26.0% vs. 4.0%) for patients receiving regorafenib as compared to placebo.(1)

Per the recommendation from an independent Data Monitoring Committee, the
'/>"/>

SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...   Taiho Oncology, Inc. , a subsidiary ... ), announced that the U.S. Food and ... TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an ... treatment of refractory metastatic colorectal cancer (mCRC), and ... submission to the FDA. According to the American ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... Oct. 19, 2014  Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... in Iwase Dental Supply, Inc., a leading full-service provider ... marks Henry Schein,s entrance into Japan ... and increases to 28 the number of countries in ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
... 5 Only about a third of American women ... means they are likely missing out on potentially important ... vitamins, minerals and fiber, fruits and vegetables contain a ... support women,s health including breast and ovarian health.   ...
... Accuray Incorporated (Nasdaq: ARAY ), ... that the company was awarded a $1 million Small Business ... used toward further development of a high-energy X-ray source for ... development of a next generation, compact X-ray source with unprecedented ...
Cached Medicine Technology:Shortfalls in Carotenoid Intake May Impact Women's Health 2Shortfalls in Carotenoid Intake May Impact Women's Health 3Shortfalls in Carotenoid Intake May Impact Women's Health 4Shortfalls in Carotenoid Intake May Impact Women's Health 5Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... hc1.com today announced the launch of ... enables healthcare organizations of all sizes to immediately ... management (“CRM”) solution. , Designed from the ground ... healthcare industry, the hc1 Healthcare Relationship Cloud™ personalizes ... combining healthcare CRM, HIPAA-compliant collaboration, and real-time analytics ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... ... ... ... BLOOMINGTON, Minn. , March 18 As part of National Colorectal Cancer Awareness Month, four health organizations have kicked off an initiative to increase screenings for Minnesotans at risk ...
... PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH),  a ... it has raised $24.4 million in a private ... $0.00001 per share, to accredited investors at a ... approximate 17% discount to the average closing price of the ...
... , ... of data protection tools for VMWare platform, announced the release and availability of SnapShot Backup ... customers to use SAN snapshots and replicas for data backup and file level restore., ... (PRWEB) March 18, 2010 -- ...
... March 18, 2010 Elbit Imaging,Ltd. ("EI") (NASDAQ: ... Services, has informed EI that its "A2/Stable" rating,on a local scale, ... principal amount of up to NIS 100 million that ... in 2010. This credit rating,would also apply to additional debentures in ...
... , ... another 81,000 SF to its portfolio and plans $500,000 in improvements to the property. ... , ... 2010 -- Ensemble Healthcare Properties (an affiliate of locally based Ensemble DevMan of Arizona) in ...
... Wendei Spale, ... Cancer. ,She provides oncology patients with the comfort and relief that has not previously been ... suit their individual needs, at her wonderfully private studio, Peace of Mind Skin Care. , ... Studio City, CA (PRWEB) ...
Cached Medicine News:Health News:Minnesota Organizations Join Together to Save 500 Lives 2Health News:Minnesota Organizations Join Together to Save 500 Lives 3Health News:Minnesota Organizations Join Together to Save 500 Lives 4Health News:Minnesota Organizations Join Together to Save 500 Lives 5Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 2Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 3Health News:PROLOR Biotech Announces Sale of $24.4 Million of Common Stock 4Health News:SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less? 2Health News:SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less? 3Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 2Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 3Health News:Midroog Ltd., an Affiliate of Moody's Investors Services, Rates Potential new Debt of Elbit Imaging 4Health News:Ensemble Healthcare Properties Purchases North Valley Medical Plaza 2Health News:Ensemble Healthcare Properties Purchases North Valley Medical Plaza 3Health News:Peace of Mind Skin Care Announces new Services in Oncology Esthetics 2
... The assay is an immunometric ... measurement of Prolactin in human ... the sample is bound by ... different epitopes. One antibody is ...
... hormone secreted in significant amounts by the ... in synergy with estrogen, plays an important ... of mammary gland growth and lactation in ... effects on cell growth in other tissues ...
... The AxSYM BNP assay allows ... in the status of your heart ... BNP versus NT-ProBNP. The AxSYM BNP ... fast, simple, walk-away resultson a platform ...
... this Enzyme ImmunoAssay (EIA) is as follows: ... on a 96 well microtiter plate. After ... the trapped molecule is covalently linked to ... After washing and denaturing treatment, Angiotensin II ...
Medicine Products: